Herbert Loong, Clinical Associate Professor at The Chinese University of Hong Kong, and Steering Committee Member at Lung Cancer Policy Network, shared a post on LinkedIn:
“Second talk at ESMO25 this year focusing on recent advancements of Antibody Drug Conjugates and Small Molecule Inhibitors in HER2 positive NSCLC.
A pleasure to be able to put this year’s thoracicmalignancies programme together with a stellar team of scientific committee members and track chairs.”
More posts about ESMO Asia 2025.
